Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$31.32 USD
+1.64 (5.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.33 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.32 USD
+1.64 (5.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.33 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for July 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 9th
Celldex Therapeutics, Inc. (CLDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Celldex Therapeutics, Inc. (CLDX).
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLDX) Outperforming Other Medical Stocks This Year?
Is Celldex Therapeutics, Inc. (CLDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex (CLDX) Soars: Stock Adds 10% in Session
by Zacks Equity Research
Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug
by Zacks Equity Research
The FDA grants accelerated nod to Seattle Genetics' (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with advanced unresectable metastatic HER2-positive breast cancer.
Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis
by Zacks Equity Research
The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
by Zacks Equity Research
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
by Zacks Equity Research
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
UroGen (URGN) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
Celldex (CLDX) Down 3.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% and -56.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Celldex (CLDX) Down 2.3% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD
by Zacks Equity Research
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Mallinckrodt Enrolls First Patient in Liver Disease Study
by Zacks Equity Research
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
Regeneron Ebola Treatment Shows Promise, Study Stopped Early
by Zacks Equity Research
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.